HIV seroconversions in the PrEP impact trial

被引：0
|
作者：
Cartier, A. [1 ]
Milinkovic, A. [1 ]
Pereira, B. [1 ]
Reeves, I. [2 ]
Ogaz, D. [3 ]
Mitchell, H. [3 ]
Saunders, J. [3 ,4 ]
Charlett, A. [3 ]
Chiavenna, C. [3 ]
Sullivan, A.
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Homerton Healthcare NHS Fdn Trust, London, England
[3] UK Hlth Secur Agcy, London, England
[4] Cent & North West London NHS Fdn Trust, London, England
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
432
引用
收藏
页码：498 / 499
页数：2
相关论文
共 50 条
  • [1] HIV seroconversions on PrEP in a major inner-city clinic population
    Stellbrink, Hans-Juergen
    Sabranski, Michael
    Buhk, Thomas
    Schewe, Knud
    INFECTION, 2021, 49 (SUPPL 1) : S46 - S46
  • [2] Characterizing HIV seroconversions among a cohort of oral PrEP users in South Africa
    Martin, Catherine E.
    Ramatsoma, Hlologelo
    Chidumwa, Glory
    Cox, Laura Ashleigh
    Mullick, Saiqa
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2025, 28 (02)
  • [3] PrEP for HIV: grade A for evidence but pending for impact
    Jared M. Baeten
    Nature Reviews Urology, 2019, 16 : 570 - 571
  • [4] Calcutta HIV Model Projections and the Impact of PrEP
    Mukandavire, Zindoga
    Mitchell, Kate
    Jana, Smarajit
    Vickerman, Peter
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A70 - A71
  • [5] Pharmacy model impact on HIV PrEP persistence
    Whelchel, Kristen
    Zuckerman, Autumn
    DeClercq, Josh
    Choi, Leena
    Kelly, Sean
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 : 32 - 33
  • [6] PrEP for HIV: grade A for evidence but pending for impact
    Baeten, Jared M.
    NATURE REVIEWS UROLOGY, 2019, 16 (10) : 570 - 571
  • [7] HIV PREP: RETENTION IN CARE HIGHER AMONG IMPACT-PREP PARTICIPANTS
    Port, Jessica
    Holmes, Sarah
    Duncan, Sarah
    SEXUALLY TRANSMITTED INFECTIONS, 2022, 98 : A66 - A67
  • [8] STI incidence among participants in the HIV Pre-Exposure Prophylaxis (PrEP) impact trial in England
    Chiavenna, C.
    Mitchell, H. D.
    Osman, R.
    Mason, E.
    Hibbert, M. P.
    Enayat, Q.
    Cartier, A.
    Jaffer, S.
    Diamente, V.
    Golombek, R.
    Estcourt, C.
    Sabin, C.
    Saunders, J.
    Charlett, A.
    Sullivan, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 40 - 41
  • [9] HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial
    Sullivan, A.
    Chiavenna, C.
    Cartier, A.
    Jaffer, S.
    Mitchell, H.
    Ogaz, D.
    Mason, E.
    Osman, R.
    Coukan, F.
    Diamente, V.
    Golombek, R.
    Richardson, D.
    Strachan, S.
    Manavi, K.
    McCormack, S.
    Priestley, C.
    Waters, L.
    Estcourt, C.
    Gold, D.
    Goldberg, D.
    Peto, T.
    Rodger, A.
    Sabin, C.
    Charlett, A.
    Desai, M.
    Saunders, J.
    Gill, N.
    HIV MEDICINE, 2021, 22 : 38 - 39
  • [10] Distance travelled to access pre-exposure prophylaxis (PrEP) for HIV prevention on the PrEP Impact trial in England during 2017-2020
    Mason, E.
    Osman, R.
    Hibbert, M.
    Enayat, Q.
    Mitchell, H.
    Chiavenna, C.
    Saunders, J.
    Sullivan, A.
    Chhibbar, P.
    Golombek, R.
    McCormack, S.
    Desai, M.
    Manavi, K.
    HIV MEDICINE, 2021, 22 : 47 - 48
12345